Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2016 1
2018 3
2019 1
2020 1
2021 1
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Imaging in Cancer Drug Development.
Waaijer SJH, Kok IC, Eisses B, Schröder CP, Jalving M, Brouwers AH, Lub-de Hooge MN, de Vries EGE. Waaijer SJH, et al. J Nucl Med. 2018 May;59(5):726-732. doi: 10.2967/jnumed.116.188045. Epub 2018 Jan 25. J Nucl Med. 2018. PMID: 29371402 Free article. Review.
89Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted 227Th-Conjugate Therapy in Mice.
Broer LN, Knapen DG, Suurs FV, Moen I, Giesen D, Waaijer SJH, Indrevoll B, Ellingsen C, Kristian A, Cuthbertson AS, de Groot DA, Cole PE, de Vries EGE, Hagemann UB, Lub-de Hooge MN. Broer LN, et al. Among authors: waaijer sjh. J Nucl Med. 2022 Nov;63(11):1715-1721. doi: 10.2967/jnumed.121.263079. Epub 2022 Apr 14. J Nucl Med. 2022. PMID: 35422447 Free article.
Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.
Ogasawara A, Kiefer JR, Gill H, Chiang E, Sriraman S, Ferl GZ, Ziai J, Bohorquez SS, Guelman S, Wang X, Yang J, Phan MM, Nguyen V, Chung S, Yu C, Tinianow J, Waaijer SJH, De Crespigny A, Marik J, Boswell CA, Zabka T, Staflin K, Williams SP. Ogasawara A, et al. Among authors: waaijer sjh. Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):287-301. doi: 10.1007/s00259-022-05968-6. Epub 2022 Oct 22. Eur J Nucl Med Mol Imaging. 2023. PMID: 36271158
Correction to: Preclinical development of ZED8, an 89Zr immuno‑PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.
Ogasawara A, Kiefer JR, Gill H, Chiang E, Sriraman S, Ferl GZ, Ziai J, Bohorquez SS, Guelman S, Wang X, Yang J, Phan MM, Nguyen V, Chung S, Yu C, Tinianow J, Waaijer SJH, De Crespigny A, Marik J, Boswell CA, Zabka T, Staflin K, Williams SP. Ogasawara A, et al. Among authors: waaijer sjh. Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):631. doi: 10.1007/s00259-022-06050-x. Eur J Nucl Med Mol Imaging. 2023. PMID: 36427067 No abstract available.
89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake.
Moek KL, Waaijer SJH, Kok IC, Suurs FV, Brouwers AH, Menke-van der Houven van Oordt CW, Wind TT, Gietema JA, Schröder CP, Mahesh SVK, Jorritsma-Smit A, Lub-de Hooge MN, Fehrmann RSN, de Groot DJA, de Vries EGE. Moek KL, et al. Among authors: waaijer sjh. Clin Cancer Res. 2019 Jun 15;25(12):3517-3527. doi: 10.1158/1078-0432.CCR-18-2918. Epub 2019 Feb 11. Clin Cancer Res. 2019. PMID: 30745297
12 results